- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01535222
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery
A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective CABG Surgery
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This protocol describes a study of the investigational drug MDCO-2010 as a haemostasis modulator in patients undergoing elective Coronary Artery Bypass Graft (CABG) surgery involving a cardiopulmonary bypass (CPB).
Perioperative bleeding is a serious complication that adversely affects the morbidity and mortality of cardiac surgery. To alleviate this complication, prophylactic antifibrinolytic therapies are now widely accepted as a strategy to inhibit excessive fibrinolysis.
MDCO-2010, a synthetic small molecule, is a direct inhibitor of plasmin and plasma kallikrein. Both of these have been implicated with impaired haemostasis. In addition, potent inhibition of coagulation factors Xa, XIa and activated Protein C has been demonstrated. Thus, MDCO-2010 has the potential to mitigate excessive fibrinolysis and thrombin generation during cardiac surgery involving a cardiopulmonary bypass. In particular the latter is supposed to provide additional benefits beyond reducing transfusion requirements.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
- Men, aged 18 to 80 years or
- Post-menopausal women, aged up to 80 years. Postmenopausal status defined as ≥ 1 year since last menstruation in women with no medical history of hysterectomy or women with a medical history of bilateral oophorectomy
- Planned elective, isolated primary CABG surgery with more than 1 graft, including the use of cardiopulmonary bypass
- Written informed consent prior to any study-related procedure not part of normal medical care
Exclusion Criteria
Patients may not meet any of the following exclusion criteria:
- Planned concomitant surgery including atrial septal defect (ASD) repair, valve replacement, carotid endarterectomy, aortic surgery, any combined procedure or any repeat sternotomy
- Planned Off-pump CABG
- Body weight < 55 kg or > 110 kg
- Planned hypothermia < 28°C
- Major surgical procedures within 30 days of entry
- Placement of drug-eluting stent (DES) within 12 months or of bare-metal stent (BMS) within 6 weeks of entry in a vessel which is not intended to be grafted
- Ejection fraction < 35%
Preoperative coagulation abnormalities
- Platelet count < 100,000/cubic mm, or
- INR > 1.5 or Quick < 40%, or
- activated partial thromboplastin time (aPTT) > 1.5 x upper limit of normal (ULN)
- Preoperative Hb < 11 g/dL for male patients or < 10 g/dL for female patients
- Patient refusal to receive donor blood products if necessary
- Administration of thienopyridines within 5 days prior to surgery Administration of warfarin within 5 days prior to surgery
- Administration of tirofiban or eptifibatide within 24 hours or administration of abciximab within 5 days prior to surgery
- Administration of fondaparinux within 24 hours prior to surgery
- Creatinine clearance (calculated using Cockroft-Gault equation) < 60 mL/min
- Planned intraoperative use of tranexamic acid or of ε-aminocaproic acid
- History of stroke or transient ischemic attack within 3 months prior to entry
- Known heparin-induced thrombocytopenia
- Known history of thrombophilia, eg, deep vein thrombosis (DVT) with pulmonary embolism
- Active liver disease
- Any condition requiring chronic immunosuppressive medication
- Receipt of an investigational drug or device 30 days prior to entry
- Any other condition which, in the opinion of the investigator, would prevent a patient's participation in the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Cohort 1
3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Altri nomi:
|
Sperimentale: Cohort 2
3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Altri nomi:
|
Sperimentale: Cohort 3
6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Altri nomi:
|
Sperimentale: Cohort 4
6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Altri nomi:
|
Sperimentale: Cohort 5
6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Altri nomi:
|
Comparatore placebo: Placebo
8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
|
Commercially available NaCl
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Incidence of Adverse Events
Lasso di tempo: 7 days (day of surgery to day 7)
|
Number of patients experiencing Adverse Events
|
7 days (day of surgery to day 7)
|
Incidence of Serious Adverse Events
Lasso di tempo: 7 days (day of surgery to day 7)
|
Number of patients experiencing Serious Adverse Events
|
7 days (day of surgery to day 7)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Lars Englberger, PD Dr. Med., University Hospital Inselspital, Bern
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- TMC-CU-10-01
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Bypass cardiopolmonare
-
Nanjing First Hospital, Nanjing Medical UniversityCompletatoBypass cardiopolmonare | Bypass con innesto dell'arteria coronariaCina
-
Università Vita-Salute San RaffaeleCompletatoChirurgia cardiaca | Bypass con innesto dell'arteria coronaria | Bypass aortocoronaricoCroazia, Italia, Cina, Malaysia, Federazione Russa, Portogallo, Bahrein, Brasile, Bulgaria, Cechia, Egitto, Arabia Saudita, Serbia
-
Mayo ClinicCompletatoBypass gastrico Roux-en-Y | Bypass gastrico | Chirurgia bariatricaStati Uniti
-
Baxter Healthcare CorporationCompletatoBypass cardiopolmonare | Sternotomia | Chirurgia cardiaca che richiede bypass cardiopolmonare e sternotomia medianaStati Uniti
-
Loma Linda UniversityCompletatoBypass cardiopolmonareStati Uniti
-
University of VirginiaNational Institute for Biomedical Imaging and Bioengineering (NIBIB)SconosciutoBypass coronaricoStati Uniti
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaTerminato
-
Umeå UniversityCompletatoBypass cardiopolmonareSvezia
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)CompletatoBypass coronaricoStati Uniti
-
Imperial College LondonSconosciuto
Prove cliniche su MDCO-2010
-
The Medicines CompanyTerminatoSanguinamentoGermania, Svizzera
-
Guangdong Hengrui Pharmaceutical Co., LtdCompletato
-
Assiut UniversityNon ancora reclutamento
-
Pharmazz, Inc.Non ancora reclutamentoSindrome da distress respiratorio acuto COVID-19
-
Pharmazz, Inc.Non ancora reclutamento
-
Chang Gung Memorial HospitalCompletato
-
Pharmazz, Inc.Completato
-
KarmelSonix Ltd.Sconosciuto
-
The Medicines CompanyThe Cleveland ClinicCompletatoSindrome coronarica acutaPolonia, Olanda, Ungheria, Canada, Cechia
-
Guangdong Hengrui Pharmaceutical Co., LtdReclutamentoNefropatia IgA primariaCina